{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:51Z","timestamp":1790996571930,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008599","name":"Alzheimerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004032","name":"Parkinson Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007687","name":"Svenska L\u00e4kares\u00e4llskapet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005701","name":"\u00c5hl\u00e9n-stiftelsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010815","name":"Stiftelsen f\u00f6r Gamla Tj\u00e4narinnor","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010815","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003554","name":"Lundbeckfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011898","name":"Marianne and Marcus Wallenberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011898","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010823","name":"Tore Nilsons Stiftelse f\u00f6r Medicinsk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010823","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2012-2172"],"award-info":[{"award-number":["2012-2172"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2010-6745"],"award-info":[{"award-number":["2010-6745"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2011-4519"],"award-info":[{"award-number":["2011-4519"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008444","name":"Parkinsonfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008444","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.nbd.2014.05.009","type":"journal-article","created":{"date-parts":[[2014,5,20]],"date-time":"2014-05-20T05:47:11Z","timestamp":1400564831000},"page":"134-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":135,"special_numbering":"C","title":["Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice"],"prefix":"10.1016","volume":"69","author":[{"given":"Veronica","family":"Lindstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Fagerqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stina","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Johannesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Schell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp J.","family":"Kahle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"M\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4r","family":"Gellerfors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Lannfelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ingelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2014.05.009_bb0005","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/S1474-4422(10)70213-1","article-title":"Are synucleinopathies prion-like disorders?","volume":"9","author":"Angot","year":"2010","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0010","doi-asserted-by":"crossref","first-page":"13454","DOI":"10.1523\/JNEUROSCI.1292-12.2012","article-title":"Antibody-aided clearance of extracellular alpha-synuclein prevents cell-to-cell aggregate transmission","volume":"32","author":"Bae","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.05.009_bb0015","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0196-9781(02)00261-9","article-title":"Passage of amyloid beta protein antibody across the blood\u2013brain barrier in a mouse model of Alzheimer's disease","volume":"23","author":"Banks","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.nbd.2014.05.009_bb0020","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ana.22421","article-title":"The blood\u2013spinal cord barrier: morphology and clinical implications","volume":"70","author":"Bartanusz","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0025","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00401-010-0664-3","article-title":"Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders","volume":"119","author":"Beach","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00401-007-0193-x","article-title":"Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons","volume":"113","author":"Braak","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1073\/pnas.97.2.571","article-title":"Acceleration of oligomerization, not fibrillization, is a shared property of both a-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy","volume":"97","author":"Conway","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2014.05.009_bb0040","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.1063522","article-title":"Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct","volume":"294","author":"Conway","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.nbd.2014.05.009_bb0045","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1523\/JNEUROSCI.2617-07.2007","article-title":"Different species of alpha-synuclein oligomers induce calcium influx and seeding","volume":"27","author":"Danzer","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.05.009_bb0055","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1471-4159.2009.06324.x","article-title":"Seeding induced by alpha-synuclein oligomers provides evidence for spreading of alpha-synuclein pathology","volume":"111","author":"Danzer","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2014.05.009_bb0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1750-1326-7-42","article-title":"Exosomal cell-to-cell transmission of alpha synuclein oligomers","volume":"7","author":"Danzer","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2014.05.009_bb0060","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00401-012-1028-y","article-title":"Spinal cord lesions in sporadic Parkinson's disease","volume":"124","author":"Del Tredici","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"34","key":"10.1016\/j.nbd.2014.05.009_bb0215","doi-asserted-by":"crossref","first-page":"11750","DOI":"10.1523\/JNEUROSCI.0234-12.2012","article-title":"Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation","volume":"32","author":"Di\u00f3genes","year":"2012","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.05.009_bb0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jnc.12175","article-title":"Monoclonal antibodies selective for alpha-synuclein oligomers\/protofibrils recognize brain pathology in Lewy body disorders and alpha-synuclein transgenic mice with the disease-causing A30P mutation","volume":"126","author":"Fagerqvist","year":"2013","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2014.05.009_bb0075","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.neurobiolaging.2006.06.013","article-title":"Age-dependent cognitive decline and amygdala pathology in alpha-synuclein transgenic mice","volume":"28","author":"Freichel","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.nbd.2014.05.009_bb0080","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","article-title":"Parkinson's disease: a dual-hit hypothesis","volume":"33","author":"Hawkes","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0085","doi-asserted-by":"crossref","first-page":"6365","DOI":"10.1523\/JNEUROSCI.20-17-06365.2000","article-title":"Subcellular localization of wild-type and Parkinson's disease-associated mutant -synuclein in human and transgenic mouse brain","volume":"20","author":"Kahle","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.05.009_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/BF00690978","article-title":"Lewy bodies in cerebral cortex, report of three cases","volume":"42","author":"Kosaka","year":"1978","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0095","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1212\/WNL.37.7.1253","article-title":"Parkinson's disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells","volume":"37","author":"Kupsky","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2014.05.009_bb0220","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s00401-014-1256-4","article-title":"Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials","volume":"127","author":"Mandler","year":"2014","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0105","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1038\/cddis.2012.94","article-title":"Alpha-synuclein: from secretion to dysfunction and death","volume":"3","author":"Marques","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.nbd.2014.05.009_bb0120","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1126\/science.287.5456.1265","article-title":"Dopaminergic loss and inclusion body formation in a-synuclein mice: implications for neurodegenerative disorders","volume":"287","author":"Masliah","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.nbd.2014.05.009_bb0225","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2014.05.009_bb0115","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2014.05.009_bb0125","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.expneurol.2008.06.004","article-title":"Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration","volume":"213","author":"Mollenhauer","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0145","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.bbrc.2008.12.005","article-title":"The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links alpha-synuclein causing rapid formation of stable oligomers","volume":"378","author":"N\u00e4sstr\u00f6m","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.nbd.2014.05.009_bb0140","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.freeradbiomed.2010.11.027","article-title":"The lipid peroxidation products 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote the formation of alpha-synuclein oligomers with distinct biochemical, morphological, and functional properties","volume":"50","author":"N\u00e4sstr\u00f6m","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.nbd.2014.05.009_bb0130","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1172\/JCI200215777","article-title":"Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies","volume":"110","author":"Neumann","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.nbd.2014.05.009_bb0135","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0065-2776(07)96005-8","article-title":"Fc-receptors as regulators of immunity","volume":"96","author":"Nimmerjahn","year":"2007","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0150","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/BF00294619","article-title":"Lewy bodies in the lower sacral parasympathetic neurons of a patient with Parkinson's disease","volume":"80","author":"Oyanagi","year":"1990","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0155","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1093\/brain\/awn349","article-title":"Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies","volume":"132","author":"Paleologou","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.nbd.2014.05.009_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/00207454.2011.613551","article-title":"Involvement of the spinal cord in Parkinson's disease","volume":"122","author":"Raudino","year":"2012","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.nbd.2014.05.009_bb0165","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0896-6273(03)00024-2","article-title":"The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease","volume":"37","author":"Sharon","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2014.05.009_bb0170","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1440-1789.2011.01211.x","article-title":"Lewy body-related alpha-synucleinopathy in the spinal cord of cases with incidental Lewy body disease","volume":"32","author":"Tamura","year":"2012","journal-title":"Neuropathology"},{"key":"10.1016\/j.nbd.2014.05.009_bb0175","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1074\/jbc.M310994200","article-title":"Aggresomes formed by alpha-synuclein and synphilin-1 are cytoprotective","volume":"279","author":"Tanaka","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2014.05.009_bb0180","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1212\/WNL.0b013e3181fd613b","article-title":"Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease","volume":"75","author":"Tokuda","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.nbd.2014.05.009_bb0185","doi-asserted-by":"crossref","first-page":"10737","DOI":"10.1074\/jbc.M010907200","article-title":"Evidence for a partially folded intermediate in alpha-synuclein fibril formation","volume":"276","author":"Uversky","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.nbd.2014.05.009_bb0190","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1523\/JNEUROSCI.20-16-06021.2000","article-title":"Neuropathology in mice expressing human -synuclein","volume":"20","author":"van der Putten","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.05.009_bb9000","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00401-013-1114-9","article-title":"Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease","volume":"125","author":"Wagner","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0195","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/039463200902200405","article-title":"Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils","volume":"22","author":"Wilms","year":"2009","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.nbd.2014.05.009_bb0200","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1073\/pnas.1100976108","article-title":"In vivo demonstration that alpha-synuclein oligomers are toxic","volume":"108","author":"Winner","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2014.05.009_bb0205","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1096\/fj.04-2751com","article-title":"Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease","volume":"19","author":"Zhang","year":"2005","journal-title":"FASEB J."},{"key":"10.1016\/j.nbd.2014.05.009_bb0210","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1074\/jbc.M403129200","article-title":"The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils","volume":"279","author":"Zhu","year":"2004","journal-title":"J. Biol. Chem."}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996114001272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996114001272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:50:00Z","timestamp":1772473800000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996114001272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":43,"alternative-id":["S0969996114001272"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2014.05.009","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy targeting \u03b1-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] \u03b1-synuclein mice","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2014.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}